VanEck Vectors Pharmaceutical ETF  |  NYSEARCA
52wk high:62.22
52wk low:50.35
Expense Ratio:0.35%
Div Frequency:Quarterly
Div Rate (ttm):1.13
Yield (ttm):1.93%
Assets (AUM):$291.55M
  • Apr. 22, 2014, 12:14 PM
    Apr. 22, 2014, 12:14 PM
  • Dec. 14, 2011, 7:50 AM
    Fitch is establishing a negative 2012 outlook for pharmaceutical companies, arguing soft demand, patent expirations, and government spending cuts will take a toll on the industry; the patent expirations (I, II, III) are seen affecting LLY, BMY, and PFE the most. Fitch also sees pharmas responding to these challenges by stepping up their M&A activity. Dec. 14, 2011, 7:50 AM